Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Lavernia

Adult Reconstructive Orthopaedic Surgery Miami, FL Medical Doctor

NPI 1255326179 CMS profile 102482

2600 Sw 3Rd Ave Ste 600, Miami, FL 33129

Open in the dashboard

General payments

$5,446,311

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Lavernia of Miami, FL is reported in the CMS Open Payments database as having received $5,446,311 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $886,507 8
2024 General $856,800 4
2023 General $729,477 6
2022 General $631,900 5
2021 General $735,529 12
2020 General $1,089,932 27
2019 General $516,165 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Lavernia
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Carlos Lavernia were reported at $886,507. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Carlos Lavernia Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $516,165 $1,416 $292–$9,336 $163
2020 $1,089,932 $647 $141–$6,474 $114
2021 $735,529 $1,073 $211–$6,497 $132
2022 $631,900 $1,217 $236–$6,299 $149
2023 $729,477 $1,082 $246–$6,818 $160
2024 $856,800 $1,575 $323–$8,944 $164
2025 $886,507 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,445,021 107 payments
  2. Intellijoint Surgical Inc. $750 1 payment
  3. Smith+Nephew, Inc. $148 1 payment
  4. Zimmer Biomet Holdings, Inc. $148 2 payments
  5. Pacira Pharmaceuticals Incorporated $122 1 payment
  6. Horizon Therapeutics plc $121 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $5,361,788 31 payments
  2. Consulting Fee $79,875 45 payments
  3. Travel and Lodging $3,005 10 payments
  4. Food and Beverage $1,643 27 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $3,832,758 28 payments
  2. MAKO Knees, Hips $1,599,189 60 payments
  3. TRIATHLON Knees $5,779 7 payments
  4. NA $4,000 1 payment
  5. TRIATHLON Knees $2,500 1 payment
  6. REUNION $1,458 11 payments
  7. Intellijoint HIP $750 1 payment
  8. TRITANIUM $187 2 payments
  9. Legion Revision $148 1 payment
  10. Anthology $148 1 payment
  11. Other $535 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$88,389

Of which drugs: $558

Medicare patients

199

Average age 76

Services billed

1,187

121 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 41%
Depression 33%
Chronic kidney disease 28%
Osteoporosis 26%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 152 $113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record